Related Experiment Video
Updated: Apr 26, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
History of thyroid disorders in relation to clinical outcomes in atrial fibrillation
Helene Bruere1, Laurent Fauchier1, Anne Bernard Brunet1
1Service de Cardiologie, Centre Hospitalier Universitaire Trousseau et Faculté de Médecine, Université François Rabelais, Tours, France.
Insights
History of hyperthyroidism does not increase stroke risk in atrial fibrillation patients. However, hypothyroidism is linked to a higher risk of bleeding events, suggesting thyroid dysfunction doesn't need inclusion in stroke prediction models.
Area of Science:
- Cardiology
- Endocrinology
- Thrombosis
Background:
- Atrial fibrillation (AF) is a common cardiac complication of hyperthyroidism.
- The link between hyperthyroidism history and stroke risk in AF patients is not well-established.
- Thyroid dysfunction's role as a thromboembolic risk factor in AF requires further investigation.
Purpose of the Study:
- To investigate whether a history of thyroid dysfunction (hyperthyroidism or hypothyroidism) impacts thromboembolic risk in patients with atrial fibrillation.
- To determine if thyroid status influences the occurrence of stroke, systemic embolism, or bleeding events in AF patients.
Main Methods:
- A cohort of 8962 patients with atrial fibrillation was identified from an academic institution (2000-2010).
- Patients were followed for clinical events including stroke/systemic embolism and bleeding.
- Time-dependent models adjusted for confounders were used to analyze associations between thyroid status and clinical outcomes.
Main Results:
- Among 8962 patients, 141 had hyperthyroidism, 540 had hypothyroidism, and 8271 had no thyroid dysfunction.
- No significant difference in stroke/systemic embolism rates was found between patients with and without thyroid dysfunction.
- History of hypothyroidism was independently associated with a higher rate of bleeding events (HR 1.35; 95% CI, 1.02-1.79).
Conclusions:
- A history of hyperthyroidism is not an independent risk factor for stroke or systemic embolism in atrial fibrillation patients.
- Hypothyroidism in AF patients is associated with an increased risk of bleeding events.
- Thyroid dysfunction status does not appear to offer additional predictive value for thromboembolic events in AF and may not warrant inclusion in current risk models.
Background:
Atrial fibrillation is the most common cardiac complication of hyperthyroidism. The association between history of hyperthyroidism and stroke remains unclear. We sought to determine whether history of thyroid dysfunction is a thromboembolic risk factor in patients with atrial fibrillation.
Methods:
Patients with atrial fibrillation seen in an academic institution between 2000 and 2010 were identified and followed-up. Clinical events (stroke/systemic embolism, bleeding, all-cause death) were recorded and related to thyroid status and disorders. Associations were examined in time-dependent models with adjustment for relevant confounders.
Results:
Among 8962 patients, 141 patients had a history of hyperthyroidism, 540 had a history of hypothyroidism, and 8271 had no thyroid dysfunction. Mean follow-up was 929 ± 1082 days. A total of 715 strokes/systemic embolism were recorded, with no significant difference in the rates of these events in patients with a history of thyroid dysfunction vs those without thyroid problems in either univariate or multivariable analysis (hazard ratio [HR] 0.85; 95% confidence interval [CI], 0.41-1.76 for hyperthyroidism; HR 0.98; 95% CI, 0.73-1.34 for hypothyroidism). There were 791 bleeding events; history of hypothyroidism was independently related to a higher rate of bleeding events (HR 1.35; 95% CI, 1.02-1.79). No significant difference among the 3 groups was observed for the incidence of death.
Conclusions:
History of hyperthyroidism was not an independent risk factor for stroke/systemic embolism in atrial fibrillation, whereas hypothyroidism was associated with a higher risk of bleeding events. These data suggest no additional benefit from the inclusion of thyroid dysfunction in thromboembolic prediction models in atrial fibrillation.
More Related Videos
Related Concept Videos
Hyperthyroidism II: Pathophysiology
Graves Disease II: Pathophysiology
Hypothyroidism II: Pathophysiology
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Dysrhythmias V: Evaluating Dysrhythmias

